Shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) traded down 5% on Friday . The stock traded as low as $5.02 and last traded at $5.18, with a volume of 68,111 shares trading hands. The stock had previously closed at $5.45.

Several analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Catabasis Pharmaceuticls from a “buy” rating to a “hold” rating in a research note on Monday, July 18th. Cowen and Company reissued a “buy” rating on shares of Catabasis Pharmaceuticls in a research note on Wednesday, June 8th. Wedbush reaffirmed an “outperform” rating and set a $17.00 price objective (down previously from $27.00) on shares of Catabasis Pharmaceuticls in a research report on Tuesday, June 7th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Catabasis Pharmaceuticls in a research report on Wednesday, May 25th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Catabasis Pharmaceuticls has a consensus rating of “Buy” and a consensus target price of $19.05.

The firm has a 50-day moving average price of $3.88 and a 200-day moving average price of $4.99. The company’s market capitalization is $77.95 million.

Catabasis Pharmaceuticls (NASDAQ:CATB) last announced its earnings results on Thursday, May 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.03. Equities analysts expect that Catabasis Pharmaceuticls Inc. will post ($2.52) earnings per share for the current fiscal year.

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.